Juno Therapeutics and Kite Pharma have reiterated their ambition to bring CAR-T therapies to market in 2017 following the publication of fresh clinical trial data at ASCO. The stage is now nearly set for a flurry of regulatory filings and decisions over the next year or so as Juno, Kite and Novartis all race to get their CAR-T therapies in front of FDA.

Source: ASCO data advance Juno, Kite toward targeted 2017 CAR-T approvals